Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
- Patients are 18 years of age or over.
- Patients present with chemotherapy-induced symptomatic anaemia.
- Patients suffer from solid tumours, malignant lymphomas or multiple myeloma and have
developed symptomatic anaemia due to their chemotherapy
- Patients can be recruited at any time (from the first to the final chemotherapy
- Patients would be suited for a course of treatment with RetacritTM (epoetin zeta)
- Patients are not undergoing chemotherapy.
- Patients have already taken part in a RetacritTM study.
- The patients have contraindications to Retacrit(TM)
- Patients have hypersensitivity to the active principle or to one of the excipients.
- The patient presents erythroblastopenia, or 'pure red cell aplasia' (PRCA)
- Uncontrollable hypertension
- An adequate prophylaxis against thrombosis is not practicable